Last reviewed · How we verify
Dymista
At a glance
| Generic name | Dymista |
|---|---|
| Also known as | Azelastine hydrochloride and Fluticasone propionate (generic name), AZE/FLU |
| Sponsor | Mylan Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis (PHASE4)
- Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray
- Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER) (PHASE3)
- Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray (PHASE1)
- Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients
- Allergic Rhinitis Combination Pharmacotherapy Efficacy Study (PHASE4)
- A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis (PHASE2)
- Dymista Allergen Chamber - Onset of Action Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dymista CI brief — competitive landscape report
- Dymista updates RSS · CI watch RSS
- Mylan Inc. portfolio CI